© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Medpace Holdings, Inc. (MEDP) stock declined over -2.62%, trading at $531.99 on NASDAQ, down from the previous close of $546.29. The stock opened at $538.68, fluctuating between $520.88 and $538.68 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 08, 2026 | 534.82 | 538.68 | 520.88 | 531.99 | 347.45K |
| Jul 07, 2026 | 556.47 | 558.84 | 540.98 | 546.29 | 356.23K |
| Jul 06, 2026 | 554.37 | 567.91 | 542.86 | 565.09 | 234.16K |
| Jul 02, 2026 | 547.79 | 562.47 | 546.61 | 557.60 | 356.57K |
| Jul 01, 2026 | 546.51 | 555.00 | 530.98 | 543.57 | 312.64K |
| Jun 30, 2026 | 534.00 | 539.51 | 523.69 | 529.59 | 335.55K |
| Jun 29, 2026 | 530.00 | 540.00 | 522.95 | 534.72 | 390.79K |
| Jun 26, 2026 | 516.50 | 528.25 | 516.00 | 527.07 | 399.91K |
| Jun 25, 2026 | 517.87 | 533.09 | 512.55 | 519.96 | 400.88K |
| Jun 24, 2026 | 479.00 | 517.83 | 479.00 | 512.79 | 503.49K |
| Jun 23, 2026 | 455.66 | 473.83 | 450.97 | 473.48 | 312.1K |
| Jun 22, 2026 | 458.82 | 461.92 | 445.01 | 455.66 | 385.39K |
| Jun 18, 2026 | 463.05 | 463.34 | 447.95 | 460.20 | 472.67K |
| Jun 17, 2026 | 457.10 | 466.68 | 455.02 | 457.09 | 240.05K |
| Jun 16, 2026 | 467.64 | 471.37 | 455.05 | 461.60 | 224.69K |
| Jun 15, 2026 | 467.34 | 474.98 | 462.91 | 467.50 | 265.7K |
| Jun 12, 2026 | 476.86 | 479.30 | 466.41 | 467.34 | 297.22K |
| Jun 11, 2026 | 463.44 | 478.80 | 463.44 | 475.07 | 249.67K |
| Jun 10, 2026 | 465.35 | 478.00 | 458.55 | 465.73 | 278.73K |
| Jun 09, 2026 | 460.36 | 471.23 | 456.97 | 466.79 | 284.28K |
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
| Employees | 5900 |
| Beta | 1.15 |
| Sales or Revenue | $1.89B |
| 5Y Sales Change% | 2.097% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |